IXICO PLC

Report Publication Announcement • Nov 27, 2025

National Storage Mechanism | Additional information

RNS Number : 1484J

IXICO plc

27 November 2025

IXICO plc

("IXICO", the "Company" or the "Group")

Notice of 2025 Full Year Results and Investor Presentation

27 November 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging, using its AI-driven platform to help advance drug development in neurological disorders, confirms it will issue its Full Year Results for the year to 30 September 2025 on Tuesday 09 December 2025.

Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all existing and potential shareholders relating to the Full Year Results and the Company's progress and ongoing strategy via:

The Investor Meet Company platform on 09 December 2025 at 16:30 GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 GMT on 08 December 2025, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:

https://www.investormeetcompany.com/ixico-plc/register-investor

Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.

A recording of the results presentation will be made available on the Group's website.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information please contact:

IXICO plc	+44 (0) 20 3763 7499
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	+44 (0) 20 7220 0500
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBFBITMTATBBA